Kiniksa Pharmaceuticals International (KNSA) FCF Margin (2021 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported FCF Margin for 6 consecutive years, with 19.1% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, FCF Margin rose 123.0% year-over-year to 19.1%; the trailing twelve-month figure through Jun 2026 stood at 21.48% (up 894.0% YoY), and the FY2025 full-year result was 20.13%, up 1636.0% from the prior year.
• FCF Margin slipped to 19.1% in Q2 2026 per KNSA's latest filing, from 23.35% in the prior quarter.
• Across five years, FCF Margin topped out at 62.6% in Q3 2022 and bottomed at 105.91% in Q1 2022.
• Historically, FCF Margin has averaged 3.82% across 5 years, with a median of 10.07% in 2024.
• The sharpest annual moves came in 2022 and 2023: FCF Margin jumped 47563 bps in 2022, then plunged 3726 bps in 2023.
• Over 5 years, FCF Margin stood at 19.13% in 2022, then surged by 136 bps to 6.87% in 2023, then soared by 93 bps to 13.26% in 2024, then surged by 88 bps to 24.98% in 2025, then retreated by 24 bps to 19.1% in 2026.
• According to Business Quant data, FCF Margin over the past three periods registered 19.1%, 23.35%, and 24.98% for Q2 2026, Q1 2026, and Q4 2025 respectively.